Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jun
13
2022
French Insider Podcast Episode 14: French Investments in the U.S. Wine Industry [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2014
Device Advice: New Guidance From the FDA on Medical Devices and Cybersecurity Sheppard, Mullin, Richter & Hampton LLP
Aug
3
2022
The Government Seeks FCA Liability for Off-Label Use of Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2015
FDA Issues Guidance for Mobile Medical Applications: What Will be Subject to FDA Oversight and Enforcement? Sheppard, Mullin, Richter & Hampton LLP
Oct
6
2022
BREAKING NEWS: Biden to Pardon Federal Marijuana Possession Convictions Sheppard, Mullin, Richter & Hampton LLP
Feb
21
2020
California Update: New QR Code Certificate Requirements, Uptick in Enforcement Actions, and the Future of California’s Cannabis Regulators Sheppard, Mullin, Richter & Hampton LLP
Jul
14
2023
FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Sheppard, Mullin, Richter & Hampton LLP
Jul
31
2023
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Sep
1
2023
Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree? Sheppard, Mullin, Richter & Hampton LLP
Oct
11
2023
The U.S. Department of Labor Provides Guidance for Agricultural Employers on the PUMP Act Sheppard, Mullin, Richter & Hampton LLP
May
27
2020
3D-Printed Masks, Disinfecting Devices, and Simplified Ventilators – a Sampling of Tech Advances in the Age of COVID-19 from California Universities Sheppard, Mullin, Richter & Hampton LLP
Jul
27
2020
A Shot Across the Bow of the Pharmaceutical Industry: President Trump Issues a Quartet of Executive Orders on Drug Pricing that Might Eventually (OR NEVER?) Take Effect Sheppard, Mullin, Richter & Hampton LLP
May
8
2024
OIG Issues Favorable Advisory Opinion Regarding Patient Assistance Funds Sheppard, Mullin, Richter & Hampton LLP
Jul
24
2010
FDA's Regulation of Laboratory Developed Tests (LDTs) - Changes on Horizon? Sheppard, Mullin, Richter & Hampton LLP
Nov
7
2010
United States Weighs in on Myriad Genetics Case Sheppard, Mullin, Richter & Hampton LLP
Jun
21
2013
Failure To Separately Notice Consideration Of California Environmental Quality Act (CEQA) Document Violates Brown Act Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2021
California Jury Awards Millions to Cannabis Company in Antitrust Case Sheppard, Mullin, Richter & Hampton LLP
Oct
9
2013
Cloning Decision Could Lead to Copycat Litigation in the World of Racing Sheppard, Mullin, Richter & Hampton LLP
Nov
1
2021
Florida Imposes Criminal Penalties for Improper Processing of DNA Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2021
CMS Suspends Vaccine Mandate Enforcement for Healthcare Workers Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
Regulating E-Cigarettes Remains “Top Priority” For FDA Sheppard, Mullin, Richter & Hampton LLP
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Oct
12
2015
Next Rx: New Medicare Part D Initiative Advances Role of Medication Management in Reform Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2019
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2023
FDA Clarifies Approach to Pediatric Drug Development Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins